Newly Independent Myriad Diagnostics Firm Will Pursue Product Acquisitions
This article was originally published in The Gray Sheet
Executive Summary
Following completion of a spin-off of its drug business, the Myriad Genetics diagnostics group plans to spend some of its large cash reserves on product acquisitions